| Literature DB >> 30829413 |
Francesco Maura1,2,3, Luca Agnelli3,4, Daniel Leongamornlert2, Niccolò Bolli2,3,5, Wing C Chan6, Anna Dodero5, Cristiana Carniti5, Tayla B Heavican7, Alessio Pellegrinelli8, Giancarlo Pruneri8, Adam Butler2, Shriram G Bhosle2, Annalisa Chiappella9, Alice Di Rocco10, Pier Luigi Zinzani11, Francesco Zaja12, Roberto Piva13, Giorgio Inghirami13,14, Wenyi Wang15, Teresa Palomero16, Javeed Iqbal7, Antonino Neri3,4, Peter J Campbell2, Paolo Corradini3,5.
Abstract
The histological diagnosis of peripheral T-cell lymphoma (PTCL) can represent a challenge, particularly in the case of closely related entities such as angioimmunoblastic T-lymphoma (AITL), PTCL-not otherwise specified (PTCL-NOS), and ALK-negative anaplastic large-cell lymphoma (ALCL). Although gene expression profiling and next generations sequencing have been proven to define specific features recurrently associated with distinct entities, genomic-based stratifications have not yet led to definitive diagnostic criteria and/or entered into the routine clinical practice. Herein, to improve the current molecular classification between AITL and PTCL-NOS, we analyzed the transcriptional profiles from 503 PTCLs stratified according to their molecular configuration and integrated them with genomic data of recurrently mutated genes (RHOA G17V , TET2, IDH2 R172 , and DNMT3A) in 53 cases (39 AITLs and 14 PTCL-NOSs) included in the series. Our analysis unraveled that the mutational status of RHOA G17V , TET2, and DNMT3A poorly correlated, individually, with peculiar transcriptional fingerprints. Conversely, in IDH2 R172 samples a strong transcriptional signature was identified that could act as a surrogate for mutational status. The integrated analysis of clinical, mutational, and molecular data led to a simplified 19-gene signature that retains high accuracy in differentiating the main nodal PTCL entities. The expression levels of those genes were confirmed in an independent cohort profiled by RNA-sequencing.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30829413 PMCID: PMC6684242 DOI: 10.1002/ajh.25450
Source DB: PubMed Journal: Am J Hematol ISSN: 0361-8609 Impact factor: 10.047